Bank of America’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-40,000
Closed -$1.04M 7230
2018
Q4
$1.04M Hold
40,000
﹤0.01% 4376
2018
Q3
$1.27M Hold
40,000
﹤0.01% 4327
2018
Q2
$1.55M Hold
40,000
﹤0.01% 4167
2018
Q1
$1.1M Buy
40,000
+5,500
+16% +$125K ﹤0.01% 4318
2017
Q4
$624K Sell
34,500
-32,600
-49% -$532K ﹤0.01% 4794
2017
Q3
$1.08M Sell
67,100
-25,000
-27% -$392K ﹤0.01% 4451
2017
Q2
$1.28M Buy
+92,100
New +$1.33M ﹤0.01% 4257

Other funds holding HRTX

Bank of America's HRTX Position: Q1 2026 in Review

Bank of America increased its Heron Therapeutics (HRTX) stake by 20% in Q1 2026, buying an estimated $30.7K and bringing the position to 160,979 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #5481.

Bank of America first reported a position in HRTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $11M in Q1 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Bank of America held 160,979 shares of Heron Therapeutics worth $129K as of Q1 2026.
  • Bank of America bought 26,534 Heron Therapeutics shares in Q1 2026, an estimated $30.7K.
  • Heron Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5481 holding.
  • Bank of America first reported a position in Heron Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Bank of America's Heron Therapeutics position peaked at $11M in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.